Novo Nordisk A/S

New York Stock Exchange
Back to all articles
Somewhat Bearish -45

What the FTC Lawsuit Against Hims & Hers Means for Telehealth Companies

📅 On July 29, 2026, the FTC sued Hims & Hers Health alongside Utah and Los Angeles County for alleged deceptive acts.

📉 The stock price fell as much as 16% on the day the lawsuit was filed against Hims.

⚖️ The complaint alleges Hims shared sensitive health conditions with advertising platforms like Meta and Snap without proper consent.

💸 FTC claims consumers were charged immediately upon prescription generation, bypassing the promised free consultation review.

🔒 The lawsuit asserts that Hims' representations of being 'private and secure' were false regarding data sharing with ad networks.

📜 The legal theories involve Section 5 of the FTC Act and the Restore Online Shoppers' Confidence Act (ROSCA).

🔄 Hims previously faced a partnership termination with Novo Nordisk in June 2025 over deceptive Wegovy promotion.

⚠️ In February 2026, the FDA cited intent to act against Hims regarding compounded oral semaglutide products.

🏛️ The article notes that regulators are using general consumer laws rather than waiting for specific telehealth statutes.

📉 Previous enforcement actions include a $1.5M penalty on GoodRx and a $7.8M settlement with BetterHelp over data sharing.

🔍 The FTC alleges 'cancellation friction' where the cancel button was hidden until after charges were processed.

🛡️ The article advises companies to audit tracking pixels and ensure affirmative express consent for data sharing.

💰 Regulators are targeting the gap between marketing claims of clinical evaluation and actual billing architecture.

📉 State and local enforcers are increasingly joining federal actions, multiplying legal exposure for telehealth firms.

Risk Factors
  • The FTC lawsuit alleges Hims shared sensitive health data with advertising platforms like Meta and Snap without valid consent.
  • The company is accused of charging patients immediately after prescription generation, contradicting claims of free consultations.
  • Hims faces allegations of 'cancellation friction' where users could not easily cancel subscriptions before charges were processed.
  • The stock price dropped as much as 16% on the day the lawsuit was filed, indicating immediate market concern.
  • Regulators are utilizing general consumer protection laws to target telehealth marketing and data practices, closing previous compliance gaps.
  • Hims previously faced a partnership termination with Novo Nordisk due to allegations of deceptive promotion of knockoff Wegovy.
  • The FDA intervened in February 2026 regarding Hims' compounded semaglutide products, citing violations of the Federal Food, Drug, and Cosmetic Act.
  • State and local attorneys general are joining federal suits, creating a multi-jurisdictional legal risk for the company.
Full Analysis
On July 29, 2026, the Federal Trade Commission (FTC), joined by Utah and Los Angeles County, sued Hims & Hers Health, Inc. in Northern District of California. The lawsuit alleges deceptive practices regarding data sharing with advertising platforms like Meta and Snap, false claims about privacy and security, and misleading billing tactics where patients were charged before receiving meaningful clinical consultations. The stock dropped as much as 16% on the day of the filing. The article details a timeline of escalating legal pressures on Hims, including a partnership termination with Novo Nordisk in June 2025 over deceptive Wegovy promotion and an FDA intervention regarding compounded semaglutide products in February 2026. The FTC complaint specifically targets violations of Section 5 of the FTC Act and the Restore Online Shoppers' Confidence Act (ROSCA), focusing on negative-option billing, hidden cancellation friction, and the sharing of sensitive health conditions with third-party ad platforms despite assurances of privacy. The piece argues that regulators are bypassing specific telehealth statutes by using general consumer protection laws to target marketing claims, data flows, and checkout architectures. It highlights a pattern where digital health companies rely on structural gaps between management organizations and professional corporations, noting that the FTC has previously penalized similar entities like GoodRx and BetterHelp for sharing health data with advertisers. The article concludes with specific compliance takeaways for the industry, urging audits of tracking pixels, explicit consent flows, and alignment of billing sequences with clinical review promises.